國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Mesotheliomafrom research to clinica...

Bombardieri, Emilio.

Mesotheliomafrom research to clinical practice /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Mesotheliomaedited by Giovanni Luca Ceresoli, Emilio Bombardieri, Maurizio D'Incalci.
其他題名:	from research to clinical practice /
其他作者:	Ceresoli, Giovanni Luca.
出版者:	Cham :Springer International Publishing :2019.
面頁冊數:	xii, 340 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
標題:	Mesothelioma.
電子資源:	https://doi.org/10.1007/978-3-030-16884-1
ISBN:	9783030168841$q(electronic bk.)

Mesotheliomafrom research to clinical practice /
Mesotheliomafrom research to clinical practice /[electronic resource] :edited by Giovanni Luca Ceresoli, Emilio Bombardieri, Maurizio D'Incalci. - Cham :Springer International Publishing :2019. - xii, 340 p. :ill. (some col.), digital ;24 cm.

Epidemiology of mesothelioma -- Asbestos and pathophysiology of mesothelioma -- Screening issues in exposed subjects and early diagnosis -- Genetics and epigenetics of mesothelioma -- Microenvironment and immunology of mesothelioma -- Pre clinical models in mesothelioma -- Pathological diagnosis of mesothelioma -- Tissue and circulating biomarkers in mesothelioma -- Diagnostic imaging of mesothelioma -- Measuring malignant pleural mesothelioma -- Role of metabolic imaging in mesothelioma -- Staging of malignant pleural mesothelioma -- Surgery and multimodality treatment in malignant pleural mesothelioma -- Role of radiotherapy in malignant pleural mesothelioma -- Role of chemotherapy in malignant pleural mesothelioma -- Targeting angiogenesis in mesothelioma -- Targeted therapies in mesothelioma -- Mesothelin-targeting agents in mesothelioma -- Immunotherapy of mesothelioma: vaccines and cell therapy -- Immunotherapy of mesothelioma: immune checkpoints inhibitors -- Peritoneal mesothelioma: diagnosis and management -- Rare localizations of mesothelioma -- Unmet needs and future outlook of mesothelioma management.

This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management. Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease's biology, together with the availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies. This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas - e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials - and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike.

ISBN: 9783030168841$q(electronic bk.)

Standard No.: 10.1007/978-3-030-16884-1doiSubjects--Topical Terms:

483686
Mesothelioma.

LC Class. No.: RC280.L8 / M47 2019

Dewey Class. No.: 616.99424

Mesotheliomafrom research to clinical practice /
LDR:03851nmm a2200325 a 4500 001 563109
003 DE-He213
005 20190619135410.0
006 m d
007 cr nn 008maaau
008 200227s2019 gw s 0 eng d
020 $a 9783030168841$q(electronic bk.)
020 $a 9783030168834$q(paper)
024 7 $a 10.1007/978-3-030-16884-1 $2 doi
035 $a 978-3-030-16884-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L8 $b M47 2019
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99424 $2 23
090 $a RC280.L8 $b M582 2019
245 0 0 $a Mesothelioma $h [electronic resource] : $b from research to clinical practice / $c edited by Giovanni Luca Ceresoli, Emilio Bombardieri, Maurizio D'Incalci.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a xii, 340 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Epidemiology of mesothelioma -- Asbestos and pathophysiology of mesothelioma -- Screening issues in exposed subjects and early diagnosis -- Genetics and epigenetics of mesothelioma -- Microenvironment and immunology of mesothelioma -- Pre clinical models in mesothelioma -- Pathological diagnosis of mesothelioma -- Tissue and circulating biomarkers in mesothelioma -- Diagnostic imaging of mesothelioma -- Measuring malignant pleural mesothelioma -- Role of metabolic imaging in mesothelioma -- Staging of malignant pleural mesothelioma -- Surgery and multimodality treatment in malignant pleural mesothelioma -- Role of radiotherapy in malignant pleural mesothelioma -- Role of chemotherapy in malignant pleural mesothelioma -- Targeting angiogenesis in mesothelioma -- Targeted therapies in mesothelioma -- Mesothelin-targeting agents in mesothelioma -- Immunotherapy of mesothelioma: vaccines and cell therapy -- Immunotherapy of mesothelioma: immune checkpoints inhibitors -- Peritoneal mesothelioma: diagnosis and management -- Rare localizations of mesothelioma -- Unmet needs and future outlook of mesothelioma management.
520 $a This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management. Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease's biology, together with the availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies. This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas - e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials - and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike.
650 0 $a Mesothelioma. $3 483686
650 1 4 $a Oncology. $3 195181
650 2 4 $a Nuclear Medicine. $3 275838
650 2 4 $a Molecular Medicine. $3 273932
650 2 4 $a Bioinformatics. $3 194415
650 2 4 $a Human Genetics. $3 273658
650 2 4 $a Immunology. $3 189152
700 1 $a Ceresoli, Giovanni Luca. $3 848522
700 1 $a Bombardieri, Emilio. $3 275894
700 1 $a D'Incalci, Maurizio. $3 848523
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u https://doi.org/10.1007/978-3-030-16884-1
950 $a Medicine (Springer-11650)